What are your top takeaways in thoracic cancers from ESMO 2025?

1. I think that the data regarding Sac-TMT vs. frontline platinum chemotherapy was the most impactful data. With all of the caveats of a China-only study, this is the first time that we have seen an ADC demonstrate a survival advantage in this setting.
2. The other two presentations are less novel, but t...

1. OptiTROP-Lung04 compared Sac-TMT vs platinum-based chemotherapy in Chinese patients who had prior PD on EGFR-TKIs. Sac-TMT is the first ADC to demonstrate superiority over traditional chemotherapy in patients with EGFR-mutated NSCLC, first against docetaxel (OptiTROP-Lung03) as reported out in AS...

1. Local consolidation has an important role even in metastatic EGFR mutant NSCLC: LBA72 - NORTHSTAR was a very important trial, both from a practical and conceptual perspective. Both FLAURA2 & MARIPOSA established the role of 1L intensification for EGFR mutant NSCLC. NORTHSTAR explores the value of...